Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (DE:BM8)
FRANKFURT:BM8
RESEARCH TOOLSreports
Holding DE:BM8?
Track your performance easily
BM8 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€61.64 - €90.52
Previous Close€64.36
Volume0.00
Average Volume (3M)223.00
Market Cap
€12.21B
Enterprise Value€12.08B
Total Cash (Recent Filing)$1.22B
Total Debt (Recent Filing)$1.09B
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Oct 29, 2024EPS Estimate
€0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding190,382,822
10 Day Avg. Volume27
30 Day Avg. Volume223
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.30
Price to Sales (P/S)5.11
Price to Cash Flow (P/CF)27.80
P/FCF Ratio34.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.67
Enterprise Value/Gross Profit6.35
Enterprise Value/Ebitda28.92
Forecast
1Y Price Target
€96.51Price Target Upside49.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering25
BioMarin Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Intellectual PropertyBMRN's solid intellectual property position in both EU and US could result in significant royalties.
Market PositionBMN-333 is anticipated to help BMRN maintain a leading position and regain market share.
Stock ValuationThere is upside potential for the stock valuation given the current trading levels.
Bears Say
CompetitionThe convenience of TransCon CNP, which is a weekly subcutaneous injection, could be a key competitive advantage as compared to Voxzogo which is a daily subcutaneous injection.
Market ShareWe see new competitors reducing Vox US market share in achondroplasia over time, from peak 36% in 2026 to 22% in 2033.
Stock PressureTransCon CNP’s potential impact to Voxzogo’s commercial share will likely continue to put pressure on the stock.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.96% Insiders
34.53% Mutual Funds
0.33% Other Institutional Investors
41.82% Public Companies and
Individual Investors
BM8 FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was €61.64 and its highest was €90.52 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
Currently, no data Available
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Oct 29, 2024 which is in 10 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Aug 05, 2024. The company reported €0.502 earnings per share for the quarter, beating the consensus estimate of €0.327 by €0.175.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is €0.48.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 190,382,830 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of €0.502 in its last earnings report, beating expectations of €0.327. Following the earnings report the stock price went up 5.419%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 2B.
---
BioMarin Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€96.51 (49.96% Upside)
€96.51 (49.96% Upside)
Blogger Sentiment
Bullish
DE:BM8 Sentiment 81%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.84%
12-Months-Change
Fundamentals
Return on Equity
5.10%
Trailing 12-Months
Asset Growth
7.68%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BM8 Company Deck
---
BM8 Earnings Call
Q2 2024
0:00 / 0:00
---
BM8 Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BM8 Stock 12 Month Forecast
Average Price Target
€96.51
▲(49.96% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Alnylam Pharma
―
Vertex Pharmaceuticals
―
Regeneron
―
Neurocrine
―
Best Analysts Covering BM8
1 Year
1 Year Success Rate
24/48 ratings generated profit
1 Year Average Return
-1.67%
reiterated a buy rating last month
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.67% per trade.
---